MapleStory 2 Awakens the Summer Season with Biggest Update Since Launch!
Critically-acclaimed MMORPG MapleStory 2 has rolled out its eagerly anticipated Awakening Expansion Update today via the Nexon Launcher and Steam. The massive content update gives players the new melee-focused Striker class, increases the level cap, adds a second job rank for all classes, introduces new Chaos Raids and Hard Dungeons and unlocks the Eye of Lapenta, including Ascendant tier weapons, the strongest gear in the game!
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190530005127/en/
Awakening Update Banner (Graphic: Business Wire)
The astounding Striker class uses a fearless combination of kicks and punches in close quarter combat brawling. All players will receive a free character slot to begin using Striker! In addition, MapleStory 2 is increasing the level cap from 60 to 70 for players to further hone their skills. All players will also have the ability to unlock Rank 2 job skills that expand the robust experiences of all classes.
With more skills come more challenges. The expansive content update will thrust players into new Hard Dungeons and Chaos Raids, both in Normal and Hard variants. The update features six new Hard Dungeons that give players the chance to earn the Frontier, Tidemaster, and Demonwing epic gear sets. With three new Chaos Raids, players can challenge Pink Bean for the first time in MapleStory 2 and earn legendary gear sets such as Enigma, Behemoth, and Dark Vanguard. There’s a lot to earn in this update!
Last and most exciting comes Eye of Lapenta, a new area with a riveting and engaging storyline containing four Dungeons more challenging than Chaos Raids. Along with the new area comes a new customizable skill system that uses Lapenshards. Lapenshards are unique gems in one of three colors that introduce a new set of passive and active skills players can customize to unlock their full powers. Players will also be able to obtain the new level 60 Ascendant gear by clearing the last dungeon in Eye of Lapenta.
In addition, players who login before June 26, will receive a Striker Daily Wonder on the first character they log in with. Players who log-in everyday will receive even more items including a Canola Bonito ground mount, a Floating Lotus air mount, a specially made Iron Fist Knuckles weapon skin for a Striker class, and a full Hysteria Outfit skin.
Through June 26, Maplers with designated new characters will also be able to earn 3 levels every time they level up through the Summer Burning Event and earn new gear at level 60 to prepare for the challenges ahead.
To learn more about the MapleStory 2 Awakening update, please visit http://bit.ly/bw-maplestory2-awakening.
Assets:
Social Media: Twitch / Facebook / Twitter / YouTube / Website
About MapleStory 2
The latest addition to the MapleStory universe, MapleStory 2 takes players to colorful new dimensions with vibrant 3D block graphics, a robust set of playable characters, a vast skill progression system, refined customization, and world-building mechanics. MapleStory 2 is an expansive and player-centric MMORPG that offers challenging new adventures with a charmingly charismatic MapleStory twist. For more information about the game, please visit http://maplestory2.nexon.net/.
About Nexon America Inc. http://www.nexon.net
Nexon America, a subsidiary of NEXON Co., Ltd. (“Nexon”) (3659.TO) is a global leader in online games with more than 80 live games operated across more than 190 countries. Nexon America introduced micro-transactions and the free-to-play business model in 2005, and is widely credited with unmatched global expertise in sophisticated live game operations, nurturing player communities, and for sustaining titles for years, even decades. Nexon is listed on the Tokyo Stock Exchange, and the company was placed on the Nikkei Stock Index 300 in 2017.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190530005127/en/
Contact information
Wahid Lodin B/HI for Nexon
wahid_lodin@bhimpact.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK ® , a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 09:03:00 EEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least one non-class I mutation, meaning more patients would be eligible for a medicine that gets them closer to normal levels of sweat chloride,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. “CFTR modulators have already revolutionized the way we treat CF and I am encoura
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 08:02:00 EEST | Press release
Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization and further development of pridopidine in Europe and other select markets. Pridopidine is a potent and highly selective, orally administered sigma-1 receptor (S1R) agonist designed to regulate key neuroprotective mechanisms often impaired in neurodegenerative diseases such as HD and ALS. Under the terms of the agreement, Prilenia will receive an upfront payment of approximately €80 million plus up to €45 million in near-term development, regulatory, and commercial milestones. The total deal is valued at up to approximately €500 million in upfront and total milestone payments. In addition, Prilenia will receive tiered double-digit royalties on
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 08:00:00 EEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 12:36:00 EEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 20:00:00 EEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom